samedan logo

 
 
spacer
home > ict > winter 2019 > concentration-qt modelling in early phase clinical studies
PUBLICATIONS
International Clinical Trials

Concentration-QT Modelling in Early Phase Clinical Studies

Long QT syndrome is a cardiac side effect that can occur with certain pharmaceuticals. After each beat, the heart repolarises, but, with long QT syndrome, this process does not occur correctly. This can lead to a condition known as Torsadede- point arrhythmia, which can cause irregular heartbeats, fainting, and even sudden death, particularly when the patient is under stress or during exercise.

Once it was understood that drugs can cause long QT syndrome, studying cardiac repolarisation became an important part of the drug development process. Regulators now mandate assessment of whether a new drug has a tendency to prolong the QT interval as part of the clinical development process.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Andreas Lindauer has been a Senior Consultant at SGS Exprimo since 2014. He studied pharmacy at the University of Bonn, Germany, subsequently completing a PhD in clinical pharmacy, focussing on PK/ PD modelling in oncology and the central nervous system.
spacer
Dr Andreas Lindauer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nova Biomedical Launches BioProfile® FLEX2 On-Line Autosampler for Fully Automated Sampling, Analysis, and Feedback Control of up to 10 Bioreactors

Waltham, MA – Nova Biomedical is pleased to announce the launch of the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to 3 weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. The FLEX2 measures up to 16 tests including pH, gases, metabolites, osmolality, cell density, and cell viability.
More info >>

White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

 
Industry Events

Evolution Summit

4-7 May 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement